Excellent response to erlotinib in breast carcinoma with rare EGFR mutation—a case report

Abstract

Triple negative breast carcinoma is a problematic subtype with poor outcomes. Many clinical trials are underway to find possible target to increase treatment options. Epidermal growth factor receptor (EGFR) has emerged as one such molecule which is over expressed in some of these patients and can be targeted by tyrosine kinase inhibitors. We describe a diagnostically challenging case of metastatic breast carcinoma, with extensive lung disease and poor Eastern Cooperative Oncology Group (ECOG) performance status, which expressed an uncommon EGFR mutation (Exon 21L861Q) and which benefitted from erlotinib following failure of all primary treatment modalities. The case uncovers the presence of these unusual mutations in breast carcinoma and highlights the importance of performing molecular analysis and the appropriate targeted therapy. This approach can be an important problem-solving tool, especially in cases where the patient is not fit for the other standard treatment options.

Genomics of Breast Cancer Brain Metastases: A Meta-Analysis and Therapeutic Implications

“…In a preclinical study, osimertinib also showed marked efficacy in EGFR -mutated glioblastoma [ 81 ]. For a metastatic breast cancer patient with EGFR L861Q mutation in a resort situation, treatment with anti-EGFR provided 6 months of disease control [ 82 ].…”